Immunotherapy duo shows promise for advanced cancers in chinese patients
NCT ID NCT05134948
First seen Nov 01, 2025 · Last updated May 13, 2026 · Updated 23 times
Summary
This early-stage study tested a fixed-dose combination of two immunotherapy drugs, relatlimab and nivolumab, in 24 Chinese patients with advanced solid tumors that had stopped responding to standard treatments. The main goals were to check safety, how the drugs move through the body, and any signs of tumor shrinkage. While not a cure, this approach aims to help the immune system better control the cancer.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMORS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Local Institution - 0001
Beijing, Beijing Municipality, 100142, China
-
Local Institution - 0002
Fuzhou, Fujian, 350014, China
Conditions
Explore the condition pages connected to this study.